Editas Medicine (EDIT) Enterprise Value (2016 - 2025)

Editas Medicine (EDIT) has reported Enterprise Value for 11 consecutive years, with -$146.6 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Enterprise Value rose 45.67% year-over-year to -$146.6 million; the TTM figure through Dec 2025 stood at -$146.6 million (up 45.67% YoY), while the FY2025 annual figure was -$146.6 million, up 45.67% from the prior year.
• Enterprise Value rose to -$146.6 million in Q4 2025 per EDIT's latest filing, from -$165.6 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$146.6 million in Q4 2025 and bottomed at -$625.3 million in Q1 2021.
• Historically, Enterprise Value has averaged -$362.2 million across 5 years, with a median of -$333.7 million in 2022.
• Annual changes were most pronounced in 2021 — Enterprise Value sank 50.69% — and 2025, when it soared 45.67%.
• Editas Medicine's Enterprise Value stood at -$499.8 million in 2021, then jumped by 31.12% to -$344.3 million in 2022, then increased by 6.15% to -$323.1 million in 2023, then rose by 16.46% to -$269.9 million in 2024, then jumped by 45.67% to -$146.6 million in 2025.
• Business Quant data shows EDIT's Enterprise Value at -$146.6 million in Q4 2025, -$165.6 million in Q3 2025, and -$178.5 million in Q2 2025.